News · 26 weeks10%
2025-12-142026-06-07
Mix090d
No activity.
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Sonendo Inc.SCHEDULE 13G/A - Sonendo, Inc. (0001407973) (Subject)
- PRSonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating OfficerSonendo, Inc. ("Sonendo" or the "Company") (OTC:SONX), a leading dental technology company and developer of the GentleWave® System, today announced the promotion of John McGaugh to Chief Operating Officer. Mr. McGaugh previously held the position of Senior Vice President of Operations. "Since Sonendo embarked on its strategic reset in early-2024, the Company has stabilized revenue, generated significant leverage in gross margin, and meaningfully lowered total operating expenses, adjusted EBITDA loss and cash burn," stated Bjarne Bergheim, President and Chief Executive Officer of Sonendo. "John has been a significant contributor to all those improvements, and we expect he will continue to
- PRSonendo, Inc. Reports Second Quarter 2025 Financial Results and Reaffirms Financial GuidanceSonendo, Inc. ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the three-months ended June 30, 2025 and reaffirmed 2025 financial guidance. Select Second Quarter Financial Results Generated $7.4 million of total revenue for the second quarter of 2025, an 11% decline compared to the prior year period, which was expected and driven entirely by lower console sales through a smaller and more cost effective sales team; Reported an increase in gross margin to 41% for the second quarter of 2025, up 320 basis points compared to the prior year period; Reported a $3.6 million reduction in
- PRSonendo, Inc. Reports First Quarter 2025 Financial Results and Issues Financial GuidanceSonendo, Inc. ("Sonendo" or the "Company") (OTC:SONX), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the first quarter ended March 31, 2025 and issued short and long-term financial guidance. Recent Highlights Generated $7.4 million of total revenue for the first quarter of 2025, representing 5% growth compared to the prior year period; Drove a substantial increase in gross margin to 44% for the first quarter of 2025, up 1600 basis points compared to the 28% gross margin for the prior year period; Reported a 48% year-over-year improvement in Adjusted EBITDA loss to $3.9 million for the first quarter of 2025
- SECSEC Form D filed by Sonendo Inc.D - Sonendo, Inc. (0001407973) (Filer)
- PRSonendo, Inc. Announces $5.0 Million Private PlacementSonendo, Inc. (OTC:SONX) ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today announced a private placement of common stock, resulting in gross proceeds of $5.0 million (the "Private Placement"). New and existing investors, including certain directors and officers of the Company, participated in the financing. Sonendo intends to use the proceeds from the financing to expand commercial programs to drive revenue growth, continue executing ongoing business restructuring activities to further reduce operating expenses and accelerate the path to positive adjusted EBITDA and operating cash flow, to retain senior leadership and key emplo
- SECSEC Form 10-K filed by Sonendo Inc.10-K - Sonendo, Inc. (0001407973) (Filer)
- PRSonendo Inc. Reports Fourth Quarter and Full Year 2024 Financial ResultsSonendo, Inc. (OTC:SONX) ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter and year ended December 31, 2024. Quarterly Highlights Generated $8.3 million total revenue for the fourth quarter 2024; Drove substantial 1,570 and 1,260 basis points of GAAP and adjusted (non-GAAP) gross margin expansion for the fourth quarter 2024 to 41.1% and 41.3%, respectively, as compared to the prior year quarter; Significantly reduced GAAP operating loss to $5.6 million and adjusted EBITDA (non-GAAP) loss to $4.7 million for the fourth quarter 2024, an improvement of 45.2% and 45.0%, respectively,
- SECSEC Form EFFECT filed by Sonendo Inc.EFFECT - Sonendo, Inc. (0001407973) (Filer)
- SECSEC Form EFFECT filed by Sonendo Inc.EFFECT - Sonendo, Inc. (0001407973) (Filer)
- SECSEC Form S-8 POS filed by Sonendo Inc.S-8 POS - Sonendo, Inc. (0001407973) (Filer)
- SECSEC Form S-8 POS filed by Sonendo Inc.S-8 POS - Sonendo, Inc. (0001407973) (Filer)
- SECSEC Form S-8 POS filed by Sonendo Inc.S-8 POS - Sonendo, Inc. (0001407973) (Filer)
- SECSEC Form S-8 POS filed by Sonendo Inc.S-8 POS - Sonendo, Inc. (0001407973) (Filer)
- SECSEC Form S-8 POS filed by Sonendo Inc.S-8 POS - Sonendo, Inc. (0001407973) (Filer)
- SECSEC Form S-8 POS filed by Sonendo Inc.S-8 POS - Sonendo, Inc. (0001407973) (Filer)
- SECSEC Form POS AM filed by Sonendo Inc.POS AM - Sonendo, Inc. (0001407973) (Filer)
- SECSEC Form POS AM filed by Sonendo Inc.POS AM - Sonendo, Inc. (0001407973) (Filer)
- SECSEC Form SCHEDULE 13G filed by Sonendo Inc.SCHEDULE 13G - Sonendo, Inc. (0001407973) (Subject)
- 13D/GAmendment: SEC Form SC 13G/A filed by Sonendo Inc.SC 13G/A - Sonendo, Inc. (0001407973) (Subject)
- 13D/GSEC Form SC 13G filed by Sonendo Inc.SC 13G - Sonendo, Inc. (0001407973) (Subject)
- SECSEC Form 10-Q filed by Sonendo Inc.10-Q - Sonendo, Inc. (0001407973) (Filer)
- SECSonendo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sonendo, Inc. (0001407973) (Filer)
- PRSonendo, Inc. Reports Third Quarter 2024 Financial ResultsSonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Generated $8.0 million total revenue for the third quarter of 2024 and carried over a double-digit console backlog for the third straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 41.2% and 42.6%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $7.5 million and adjusted EBITDA (non-GAAP) loss to $5.1 million, a 57% and
- PRSonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will postpone the third quarter 2024 conference call that was previously scheduled for after the market close on Tuesday, November 12th, 2024. The Company still intends to file its audited financial results on November 12th, 2024, but has postponed, until further notice, the accompanying conference call. Management will provide commentary on events subsequent to the end of the quarter ending September 30th, 2024, at a later date. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth deca
SONX FAQ
7 questionsWhat does Sonendo Inc. do?
Sonendo, Inc. develops, manufactures, and sells devices for root canal therapy in the United States and Canada. It offers GentleWave, a device to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of ethylenediaminetetraacetic acid used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software. The...Where does SONX stock trade?
Sonendo Inc. (SONX) is listed on NYSE.What sector and industry is SONX in?
Sonendo Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Sonendo Inc. go public?
Sonendo Inc. (SONX) completed its IPO in 2021.What are analysts saying about SONX?
Sonendo Inc. has had 6 recent analyst actions on file. The most recent action was from Stifel: Hold on 2024-03-12. Recent price targets range from $690.00 to $3000.00.What companies are similar to SONX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare SONX side-by-side with any of them on Quantisnow.How can I track SONX on Quantisnow?
Quantisnow aggregates Sonendo Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SONX to receive live email and push alerts on every new disclosure.